164 related articles for article (PubMed ID: 25109497)
1. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
Tanaka N; Yoshida H; Suzuki Y; Harigaya K
Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
[TBL] [Abstract][Full Text] [Related]
2. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
Di Modugno F; Iapicca P; Boudreau A; Mottolese M; Terrenato I; Perracchio L; Carstens RP; Santoni A; Bissell MJ; Nisticò P
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19280-5. PubMed ID: 23129656
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
[TBL] [Abstract][Full Text] [Related]
4. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of human ortholog of mammalian enabled (hMena) is associated with the expression of mutant p53 protein in human breast cancers.
Toyoda A; Yokota A; Saito T; Kawana H; Higashi M; Suzuki Y; Tanaka T; Kitagawa M; Harigaya K
Int J Oncol; 2011 Jan; 38(1):89-96. PubMed ID: 21109929
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression.
Toyoda A; Kawana H; Azuhata K; Yu J; Omata A; Kishi H; Higashi M; Harigaya K
Int J Oncol; 2009 Jan; 34(1):53-60. PubMed ID: 19082477
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.
Bria E; Di Modugno F; Sperduti I; Iapicca P; Visca P; Alessandrini G; Antoniani B; Pilotto S; Ludovini V; Vannucci J; Bellezza G; Sidoni A; Tortora G; Radisky DC; Crinò L; Cognetti F; Facciolo F; Mottolese M; Milella M; Nisticò P
Oncotarget; 2014 Nov; 5(22):11054-63. PubMed ID: 25373410
[TBL] [Abstract][Full Text] [Related]
8. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
[TBL] [Abstract][Full Text] [Related]
9. The cooperation between hMena overexpression and HER2 signalling in breast cancer.
Di Modugno F; Mottolese M; DeMonte L; Trono P; Balsamo M; Conidi A; Melucci E; Terrenato I; Belleudi F; Torrisi MR; Alessio M; Santoni A; Nisticò P
PLoS One; 2010 Dec; 5(12):e15852. PubMed ID: 21209853
[TBL] [Abstract][Full Text] [Related]
10. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
11. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.
Pino MS; Balsamo M; Di Modugno F; Mottolese M; Alessio M; Melucci E; Milella M; McConkey DJ; Philippar U; Gertler FB; Natali PG; Nisticò P
Clin Cancer Res; 2008 Aug; 14(15):4943-50. PubMed ID: 18676769
[TBL] [Abstract][Full Text] [Related]
12. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
13. hMena: altered expression in psoriatic skin.
Cardinali G; Kovacs D; Mastrofrancesco A; Cota C; Donati P; Cordiali-Fei P; Francesconi F; Bonifati C
Arch Dermatol Res; 2013 Dec; 305(10):933-8. PubMed ID: 23604962
[TBL] [Abstract][Full Text] [Related]
14. Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.
Pignatelli J; Goswami S; Jones JG; Rohan TE; Pieri E; Chen X; Adler E; Cox D; Maleki S; Bresnick A; Gertler FB; Condeelis JS; Oktay MH
Sci Signal; 2014 Nov; 7(353):ra112. PubMed ID: 25429076
[TBL] [Abstract][Full Text] [Related]
15. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
16. Increase of GKLF messenger RNA and protein expression during progression of breast cancer.
Foster KW; Frost AR; McKie-Bell P; Lin CY; Engler JA; Grizzle WE; Ruppert JM
Cancer Res; 2000 Nov; 60(22):6488-95. PubMed ID: 11103818
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast.
Schmid BC; Rudas M; Fabjani G; Speiser P; Kaserer K; Leodolter S; Zeillinger R
Oncol Rep; 2003; 10(6):1981-5. PubMed ID: 14534730
[TBL] [Abstract][Full Text] [Related]
18. hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.
Di Modugno F; Spada S; Palermo B; Visca P; Iapicca P; Di Carlo A; Antoniani B; Sperduti I; Di Benedetto A; Terrenato I; Mottolese M; Gandolfi F; Facciolo F; Chen EI; Schwartz MA; Santoni A; Bissell MJ; Nisticò P
Oncogene; 2018 Oct; 37(42):5605-5617. PubMed ID: 29907768
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the expression of the pro-metastatic Mena(INV) isoform during breast tumor progression.
Oudin MJ; Hughes SK; Rohani N; Moufarrej MN; Jones JG; Condeelis JS; Lauffenburger DA; Gertler FB
Clin Exp Metastasis; 2016 Mar; 33(3):249-61. PubMed ID: 26680363
[TBL] [Abstract][Full Text] [Related]
20. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response.
Di Modugno F; Bronzi G; Scanlan MJ; Del Bello D; Cascioli S; Venturo I; Botti C; Nicotra MR; Mottolese M; Natali PG; Santoni A; Jager E; Nisticò P
Int J Cancer; 2004 May; 109(6):909-18. PubMed ID: 15027125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]